GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Ending Cash Position

Haemonetics (Haemonetics) Ending Cash Position : $179 Mil (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Haemonetics Ending Cash Position?

Haemonetics's Ending Cash Position for the quarter that ended in Mar. 2024 was $179 Mil.

Haemonetics's quarterly Ending Cash Position declined from Sep. 2023 ($351 Mil) to Dec. 2023 ($194 Mil) and declined from Dec. 2023 ($194 Mil) to Mar. 2024 ($179 Mil).

Haemonetics's annual Ending Cash Position increased from Mar. 2022 ($259 Mil) to Mar. 2023 ($284 Mil) but then declined from Mar. 2023 ($284 Mil) to Mar. 2024 ($179 Mil).

Haemonetics Ending Cash Position Historical Data

The historical data trend for Haemonetics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Ending Cash Position Chart

Haemonetics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 137.31 192.31 259.50 284.47 178.80

Haemonetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 284.47 285.72 351.01 193.98 178.80

Haemonetics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Haemonetics's Ending Cash Position for the fiscal year that ended in Mar. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=284.466+-105.666
=179

Haemonetics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=193.978+-15.178
=179

Haemonetics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Haemonetics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics (Haemonetics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Ending Cash Position
Comparable Companies
MMSI NVST AZTA XRAY ICUI STAA STVN WRBY LMAT ATRC ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD OCSE:COLO B WST TSE:4543 XSWX:STMN
Traded in Other Exchanges
HAZ:Germany
Address
125 Summer Street, Boston, MA, USA, 02110
Website
https://www.haemonetics.com
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277